TRUMY logo

TRUMY Terumo Corporation

Other OTC · Medical - Specialties · Healthcare

$16.67
+0.30 (+1.83%)

Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular division provides critical devices for cardiovascular and cerebrovascul…

Market Cap: $24.59Bwww.terumo.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 12Aug 12

Quote

Day Range
$16.67 – $16.76
52-Week Range
$12.08 – $19.60
Volume
$6.9K
Market Cap
$24.59B
50-Day Avg
$14.22
200-Day Avg
$14.05
Prev Close
$16.37
Open
$16.71

Valuation & Ratios

P/E Ratio
21.93
EPS
$97.70
P/B Ratio
1.98
P/S Ratio
2.63
Debt/Equity
0.24
Current Ratio
1.59
Dividend Yield
+1.4%
Gross Margin
+52.5%

Returns & Efficiency

Return on Equity
+9.1%
Return on Assets
+6.2%
FCF Yield
+4.9%
EV/EBITDA
10.95

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2026$1.20T$144.11B$97.47
2025$1.04T$116.98B$79.01
2024$921.86B$106.37B$71.50
2023$820.21B$89.33B$59.50
2022$703.30B$88.81B$58.72

Social Signal Score

50
5d
50
1 mentions
30d
50
1 mentions
60d
50
1 mentions
90d
50
1 mentions
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $0.17 per share

3of 7 quarters beat consensus

Typical surprise -0.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 7$0.30 vs $0.17beat
  • Fri, May 15$0.11 vs $0.11beat
  • Fri, Feb 13$0.14 vs $0.15miss
  • Wed, Nov 12$0.16 vs $0.16miss
  • Thu, Aug 7$0.20 vs $0.17beat
  • Wed, May 14$0.08 vs $0.15miss

Estimates and results for TRUMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

Project earnings forward and see what return today's price implies.

Seeded from TRUMY's reported EPS growth of 13.5% a year over 4 years.

EPS in 5 years
$184.02
Implied price
$4,049
Return from $16.67
200.0% a year

To earn 15.0% a year on these assumptions you'd need to buy at $2,013 — today's price is already 99.2% below that.

How sensitive is that answer?

Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.

growth \ P/E1619222528
3.5%156.7%165.6%173.5%180.6%187.1%
8.5%169.1%178.5%186.8%194.2%200.9%
13.5%181.5%191.3%200.0%207.7%214.8%
18.5%193.9%204.1%213.2%221.3%228.7%
23.5%206.3%217.0%226.4%234.8%242.5%

This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.

Mentions (1)

  • Newsseekingalpha.com·3d ago·Neutral

    Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript

    View source ↗